通过益生菌补充剂减缓阿尔茨海默氏病的进展
Destynie Medeiros1, Kristina McMurry2, Melissa Pfeiffer2
1Department of Biology, University of Hartford, West Hartford, CT, United States.
Frontiers in neuroscience
|March 21, 2024
概括
益生菌补充剂在阿尔茨海默病 (AD) 鼠标模型中改善了认知功能并减少了神经炎症. 这表明益生菌可能为早期神经退行症提供可访问的辅助疗法.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知障碍和神经退行缺少负担得起的治疗方法.
- 肠-大脑轴突出了肠道微生物群在阿尔茨海默病 (AD) 等神经系统疾病中的作用.
- 与AD相关的肠道失生症的益生菌疗法仍未得到充分研究.
研究的目的:
- 在AD小鼠模型中研究益生菌补充剂对肠道失生症的影响.
- 评估益生菌对AD小鼠神经退行症进展和认知功能的影响.
主要方法:
- 转基因3xTg-AD小鼠在12周内接受了对照或益生菌饮食 (Lactobacillus plantarum KY1032和Lactobacillus curvatus HY7601).
- 分析了肠道微生物群的组成,重点关注 Bacteroidetes 的丰富性.
- 用巴恩斯迷宫测试来评估认知功能.
- 神经组织 (脑内皮层,海马) 分析了星球细胞,微质细胞和神经元密度.
主要成果:
- 益生菌补充剂显著增加了 Bacteroidetes 的丰富性.
- 益生菌养的AD小鼠在认知测试中表现出更好的记忆性能.
- 在益生菌养的AD小鼠的大脑中观察到减少的星细胞和微质密度,特别是雌性.
- 在接受益生菌治疗的AD小鼠中,海马神经元数量的增加表明神经保护.
结论:
- 在3xTg-AD小鼠模型中,益生菌补充剂可以有效地延迟或减轻早期神经退行.
- 益生菌为阿尔茨海默病提供了潜在的廉价和易于实施的辅助疗法.
- 对神经退行性疾病的益生菌干预措施的进一步研究是有必要的.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.内皮层 (entorhinal cortex) 是一个内侧的皮层.格利亚 (Glia) 是一个.我们的肠道微生物群.在海马体内,海马体这是一种炎症炎症炎症炎症.神经退行症的神经退行症神经元神经元的神经元更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
